Project Grant R21CA302296
Award Date 8/4/25
Completion Date 7/31/27
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- The federal Cooperative Agreement award, totaling $4,234,248 and provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to comprehensively characterize the T-cell response to Kaposi Sarcoma Herpesvirus (KSHV) to enable specific immune therapy. The award, with a performance period from September 2025 to August 2029, is granted to the Fred Hutchinson Cancer Center (also known as Seattle Cancer Care Alliance) to conduct research that could lead to strategies to...
- This federal Project Grant award of $216,013, provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research aimed at investigating the effects of caspases and antiviral responses on Kaposi's sarcoma-associated herpesvirus (KSHV) tumorigenesis. The research, conducted by the University of Wisconsin-Madison, utilizes a 3D primary human endothelial cell organoid model to better understand how activation of the interferon (IFN) pathway, either through direct...
- This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) provides $411,400 to Northwestern University to develop and characterize a cell culture model of Kaposi's sarcoma (KS). The primary objective is to identify KSHV-induced cellular genes that promote the loss of contact inhibition of proliferation (CIP) in KSHV-infected lymphatic endothelial cells (KLECs), which are believed to be the cell of origin for KS tumors. The...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), aims to study the genome-wide chromatin structure and function in Kaposi sarcoma (KS) tissue. The $476,754 award, effective from July 11, 2025 to June 30, 2028, will be carried out by Barnard College, a private women's liberal arts college in New York City. The key products and services to be delivered under this grant include: 1) Identifying virus-associated host...
- The National Cancer Institute (CFDA 93.396 Cancer Biology Research) awarded a $1,349,322 Project Grant to the University of Pittsburgh to study how the Kaposi's sarcoma-associated herpesvirus (KSHV) manipulates cellular metabolic pathways, specifically the methionine/S-adenosylmethionine (SAM) cycle, to maximize viral latent and lytic infections. The project aims to identify KSHV-regulated methyltransferase METTL16-specific N6-methyladenosine (m6A) marks, delineate the mechanisms by which the...
- This Project Grant award of $188,169 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of California, Davis (UC Davis) supports the development of a gene therapy vector using the adeno-associated virus (AAV) system to target Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The goal is to selectively express therapeutic genes, such as the thymidine kinase (TK)/ganciclovir (GCV) system, in KSHV-infected tumor cells that express...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Fred Hutchinson Cancer Center in Seattle, WA will support research to understand the pathogenesis of classic Hodgkin lymphoma in persons living with HIV (PLWH). The $176,000 award will fund a 2-year study to identify persistent transcriptomic changes in immune cells from benign lymph nodes of PLWH on combination antiretroviral therapy, and compare these findings to changes in classic...
- This $877,104 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program, supports research to investigate the molecular mechanisms of Kaposi's sarcoma-associated herpesvirus (KSHV) infection and persistence. The research aims to delve deeper into how KSHV infection impacts immune cells, such as monocytes/macrophages and B cells, and how viral latency is established in B cells. Key aspects of the...
- This federal Project Grant award, with ID R01CA290700, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $564,698 award to the University of California, Davis (UC Davis) will fund a 5-year research project to investigate the role of the terminal repeat sequence in regulating the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic gene promoters. The research aims to better understand the KSHV gene regulation mechanisms, with the...
- The National Cancer Institute (NCI) awarded a $168,500 Project Grant under the "Cancer Cause and Prevention Research" (CFDA 93.393) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The two-year grant, with an ultimate completion date of July 31, 2025, aims to evaluate physical and mental health symptoms (patient-reported outcomes) throughout the cancer diagnosis trajectory and their associations with cancer outcomes among HIV-positive...